1. Home
  2. CQP vs ALNY Comparison

CQP vs ALNY Comparison

Compare CQP & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CQP
  • ALNY
  • Stock Information
  • Founded
  • CQP 2003
  • ALNY 2002
  • Country
  • CQP United States
  • ALNY United States
  • Employees
  • CQP N/A
  • ALNY N/A
  • Industry
  • CQP Oil/Gas Transmission
  • ALNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • CQP Utilities
  • ALNY Health Care
  • Exchange
  • CQP Nasdaq
  • ALNY Nasdaq
  • Market Cap
  • CQP 28.1B
  • ALNY 33.1B
  • IPO Year
  • CQP 2007
  • ALNY 2004
  • Fundamental
  • Price
  • CQP $52.29
  • ALNY $237.92
  • Analyst Decision
  • CQP Sell
  • ALNY Buy
  • Analyst Count
  • CQP 4
  • ALNY 23
  • Target Price
  • CQP $49.00
  • ALNY $298.59
  • AVG Volume (30 Days)
  • CQP 142.8K
  • ALNY 625.4K
  • Earning Date
  • CQP 10-31-2024
  • ALNY 02-13-2025
  • Dividend Yield
  • CQP 6.08%
  • ALNY N/A
  • EPS Growth
  • CQP N/A
  • ALNY N/A
  • EPS
  • CQP 4.62
  • ALNY N/A
  • Revenue
  • CQP $8,930,000,000.00
  • ALNY $2,094,795,000.00
  • Revenue This Year
  • CQP N/A
  • ALNY $25.14
  • Revenue Next Year
  • CQP $13.54
  • ALNY $17.35
  • P/E Ratio
  • CQP $11.53
  • ALNY N/A
  • Revenue Growth
  • CQP N/A
  • ALNY 21.54
  • 52 Week Low
  • CQP $45.51
  • ALNY $141.98
  • 52 Week High
  • CQP $59.40
  • ALNY $304.39
  • Technical
  • Relative Strength Index (RSI)
  • CQP 38.83
  • ALNY 34.24
  • Support Level
  • CQP $56.11
  • ALNY $241.89
  • Resistance Level
  • CQP $58.70
  • ALNY $249.58
  • Average True Range (ATR)
  • CQP 1.78
  • ALNY 6.72
  • MACD
  • CQP -0.72
  • ALNY -0.37
  • Stochastic Oscillator
  • CQP 2.07
  • ALNY 3.07

About CQP Cheniere Energy Partners LP Common Units

Cheniere Energy Partners is the direct owner of the Sabine Pass LNG terminals as well as regasification facilities. It also owns the Creole Trail Pipeline, which connects the terminal to third-party gas suppliers. Cheniere Partners shares in the marketing fees generated by Cheniere Marketing from Sabine Pass marketed gas volumes.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: